Regen Biopharma, Inc. (the "Company") has begun the process of reviving patent applications of the Company filed with the United States Patent and Trademark Office ("USPTO") which have been classified as abandoned by the USPTO.
Legal services in connection with the abovementioned revival activities are being provided by Marc Baumgartner of Baumgartner Patent Law. Mr. Baumgartner has over 20 years of experience in the field of intellectual property law.
Application/PCT #Title of InventionStatus that may be revived...
13897735 ACCELERATION OF HEMATOPOIETIC RECONSTITUTION BY PLACENTAL ENDOTHELIAL AND ENDOTHELIAL PROGENITOR CELLS Abandoned -- Failure To Respond To An Office Action
13957427 CELLS, COMPOSITIONS, AND TREATMENT METHODS FOR STIMULATION OF HEMATOPOIESIS Abandoned -- Failure To Respond To An Office Action
13957431 CANCER THERAPY BY EX VIVO ACTIVATED AUTOLOGOUS IMMUNE CELLS Abandoned -- Failure To Respond To An Office Action
14854136 STIMULATION OF IMMUNITY TO TUMOR SPECIFIC AND ENDOTHELIAL SPECIFIC PROTEINS BY IN VIVO DC ATTRACTION AND MATURATION Abandoned -- Failure To Respond To An Office Action
14954902 IMMUNE MODULATION BY TLR ACTIVATION FOR TREATMENT OF FILOVIRUS INFECTIONS INCLUDING EBOLA Abandoned -- Failure To Respond To An Office Action
15162370 ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES Response To Non-Final Office Action Entered And Forwarded To Examiner
15250877 TREATMENT OF LIVER CANCER THROUGH EMBOLIZATION DEPOT DELIVERY OF BORIS GENE SILENCING AGENTS Abandoned -- Failure To Respond To An Office Action
15364111 SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY Response To Non-Final Office Action Entered And Forwarded To Examiner
15431681 METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION Abandonment For Failure To Correct Drawings/Oath/NonPub Request
17010720 STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY Application Dispatched From Preexam, Not Yet Docketed
62363588 SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY Provisional Application Expired
Dr. Ma is a Professor of Microbiology and Immunology at Weill Cornell Medical College. With over 100 scientific papers published and large research laboratory at a premier university, Dr. Ma brings extensive expertise to Regen as we develop our NR2F6 small molecules.
?Dr. Ma has been studying cytokines, particularly the IL-10 and IL-12 family of interleukins, for more than 20 years in many aspects of their regulation and immunobiology in various inflammatory autoimmune and tumor-immune models.
Dr. Ma’s group first identified a novel function of the Crohn’s disease-associated NOD2 mutation and uncovered the mechanisms by which IL-12 induces strong cell-mediated immune responses against various malignancies. He was also the first to identify a novel, non-chemokine activity of CCL5 in the generation and function of myeloid-derived suppressor cells and tumor-associated macrophages in the regulation of immune responses against breast cancer/mammary tumor.
Cancer vaccination involves the induction of tumor-specific T-cell responses potentially capable of tumor rejection by providing cancer antigens in the context of immunostimulation. Some cancer vaccines targeting surface exposed antigens additionally aim at inducing a tumor-specific B-cell response. Antigens are either tumor-associated self antigens (TAA), such as differentiation antigens, overexpressed antigens, cancer/testis antigens, or truly tumor-specific antigens (TSAs) not subject to immune tolerance, such as viral and mutated neoantigens. Various formats can be used for antigen delivery, including viral vectors, DNA, peptides, mRNA, or dendritic cells (DCs) pulsed with any of these.
mRNA has emerged as an attractive cancer vaccine format as it provides both antigen delivery and innate immune activation-mediated co-stimulation in a spatiotemporally aligned manner. mRNA vaccines encode the full or partial sequence of a TSA or TAA, and do not rely on prior identification of a patient’s human leukocyte antigen (HLA) haplotype or epitope prediction.
The feasibility of mRNA-based cancer vaccination was first demonstrated about 25?years ago [25, 26]. Since then, numerous preclinical and clinical studies explored mRNA for anti-cancer vaccination, either by loading it ex vivo on autologous DCs for adoptive transfer or by direct injection. A summary of all active, and completed or terminated phase II and III clinical trials using mRNA vaccines is provided in Table 1.